Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
World game at war: why some European nations have threatened a World Cup boycott 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
NEW YORK, April 27, 2018 -- Kannalife Sciences, Inc. (“Kannalife”), a phyto-medical company, announced today that the Company’s CEO Dean Petkanas will be presenting at the 2018 Cannabinoids in Medicine Summit in Los Angeles on Saturday, April 28. Petkanas will be speaking on “Industry Advancements and New Frontiers – New Research Findings, Novel Drugs and Unique Delivery Systems” at 5:15pm PT.
The 2018 Cannabinoids in Medicine Summit brings together physicians, registered nurses and pharmacists engaged in the care of patients with various chronic diseases, allowing participants to learn from an elite group of experts about newer cannabinoid research and evidenced-based reviews examining the efficacy and safety of cannabinoids in critical therapeutic areas.
“At Kannalife we are always pleased to be called to participate at industry symposiums and conferences that focus on Cannabinoid therapeutics in the clinical setting.” Petkanas said “The Cannabinoid based therapeutics market is moving at a rapid pace, as seen by the recent 13-0 vote from the FDA’s advisory panel in favor of market approval for GW Pharmaceutical’s epilepsy drug EpidiolexTM. As for Kannalife, we are seeing great progress in the potential benefits of our own proprietary cannabidiol derived compound KLS-13019 in the treatment of disorders like Chemotherapy Induced Neuropathic Pain (CINP) and chronic diseases like Hepatic Enchephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE).”
About Kannalife Sciences
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
[email protected]
www.cmwmedia.com
